[1] ZHANG G， LIU A， ZHOU Y， et al. Panax ginseng ginsenoside-Rg2 protects memory impairment via anti-apoptosis in a rat model with vascular dementia [J]. J Ethnopharmacol， 2008， 115(3)：441-448.
[2] YU X T，WANG S P. Clinical observation on treatment for postoperative gastric cancer by ginsenoside Rg3 combined with chemotherapy [J]. Chin J Cancer Prev Treat(中华肿瘤防治杂志)， 2010， 17(10)：779-781.
[3] ZHANG Z， JIANG B， ZHENG X， et al. Immune enhancing effects of Rg3 on peripheral lymphocytes in vitro in cancer patients treated with radiotherapy [J]. Chin Pharm J (中国药学杂志)， 2004， 39(4)：261-264.
[4] SUI D Y， YU X F， QU S C， et al. Effects of Panax quinquefolium 20S-2protopanaxdiol saponins on experimental ventricular remodeling in rat [J]. Chin Pharm J (中国药学杂志)， 2007， 42(2)：108-112.
[5] LEE Y， JIN Y， LIM W， et al. A ginsenoside-Rh1， a component of ginseng saponin， activates estrogen receptor in human breast carcinoma MCF-7 cells [J]. J Steroid Biochem， 2003， 84(4)：463-468.
[6] WILLIAM C S， CHUNG W S， SALLY K W， et al. Ginsenoside Re of Panax ginseng possesses significant antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats [J]. Eur J Pharmacol， 2006， 550（1-3）：173-179.
[7] KIM S E， LEE Y H， PARK H J， et al. Ginsenoside-Rs4， a new type of ginseng saponin concurrently induces apoptosis and selectively elevates protein levels of p53 and p21WAF1 in human hepatoma SK-HEP-1 cells European [J]. Eur J Cancer， 1999， 35(3)：507-511.
[8] LI H， SUN J G， XIE H T， et al. Study on absorption mechanism of ginsenoside Rg1 using rat everted gut sac [J]. Chin J Clin Pharmacol Ther (中国临床药理学与治疗学)， 2004， 9(5)：510-513.
[9] FENG L， HU C J， YU L Y， et al. Pharmacokinetics of ginsenoside Rg1 and its metabolites in rats [J]. Acta Pharm Sin (药学学报)， 2010， 45(5)：636-640.
[10] LEE J， LEE E， KIM D， et al. Studies on absorption， distribution and metabolism of ginseng in humans after oral administration [J]. J Ethnopharmacol， 2009， 122(1)：143-148.
[11] YANG X W， GUI F J， TIAN J M， et al. Pharmacokinetics of ginsenoside-Rg2 in rats [J]. Chin Pharmacol Bull(中国药理学通报)， 2009， 25(7)：967-970.
[12] GUI F J， YANG X W， LI L Y， et al. Simultaneous enantiomer determination of 20 (R)- and 20 (S)-ginsenoside-Rg2 in rat plasma after intravenous administration using HPLC method [J]. J Chromatography B， 2007， 850(1-2)：1-6.
[13] HUANG Y， LIU J H. Pharmacokinetic study of ginsenoside 20(S)-Rg3 in rats by HPLC- ELSD [J]. J Pr Med Theory (实用医技杂志)， 2005， 12(9)：2564-2566.
[14] CAI Z， QIAN T， WONG R， et al. Liquid chromatography-electrospray ionization mass spectrometry for metabolism and pharmacokinetic studies of ginsenoside Rg3 [J]. Anal Chim Acta， 2003， 492(1-2)：283-293.
[15] LIU L， HUANG J， HU X， et al. Simultaneous determination of ginsenoside (G-Re， G-Rg1， G-Rg2， G-F1， G-Rh1) and protopanaxatriol in human plasma and urine by LC-MS/MS and its application in a pharmacokinetics study of G-Re in volunteers [J]. J Chromatography B， 2011， 22(15)：2011-2017.
[16] JOO K， LEE H J， JEON H Y， et al. Pharmacokinetic study of ginsenoside Re with pure ginsenoside Re and ginseng berry extracts in mouse using ultra performance liquid chromatography/mass spectrometric method [J]. J Pharmaceut Biomed， 2010， 51(1-2)：278-283.
[17] QIAN T， JIANG Z H， CAI Z. High-performance liquid chromatography coupled with tandem mass spectrometry applied for metabolic study of ginsenoside Rb1 on rat [J]. Anal Biochem， 2006， 352(1)：87-96.
[18] GU Y， WANG G J， SUN J G. Pharmacokinetic characterization of ginsenoside Rh2， an anticancer nutrient from ginseng， in rats and dogs [J]. Food Chem Toxicol， 2009， 47(9)：2257-2268.
[19] YANG L， DENG Y， XU S， et al. In vivo pharmacokinetic and metabolism studies of ginsenoside Rd [J]. J Chromatography B， 2007， 854(1-2)：77-84.
[20] WANG W， WANG G J， XIE H T， et al. Determination of ginsenoside Rd in dog plasma by liquid chromatography-mass spectrometry after solid-phase extraction and its application in dog pharmacokinetics studies [J]. J Chromatography B， 2007， 852(1-2)：8-14.
[21] JIANG J， LI S， GONG P L， et al. Pharmacokinetics of Shengmaiyin oral solution after a single dose in human [J]. Acta Med Univ Sci Technol Huazhong(华中科技大学学报医学版)， 2007， 36(2)：272-274.
[22] LIN L， ZU F Y， ZHANG W W， et al. Effects of compound compatibility on absorption in vitro of ginsenoside saponins[J]. Chin J Mod Drug Appl (中国现代药物应用)， 2010， 4(13)：150-152.
[23] LUO D F， YE J T， ZHANGY S， et al. Studies on drug release in vitro and absorption in rat in vivo of ginsenoside Rd solid lipid nanoparticles [J]. Chin Pharmacol Bull(中国药理学通报)， 2009， 25(7)：923-926.
[24] GU Y， WANG G J， SUN J G， et al. Pharmacokinetic study of ginsenoside 20(R)-Rh2 in Beagle dogs by LC-ESI-MS [J]. Chin J Clin Pharmacol Ther (中国临床药理学与治疗学)， 2006，11（3）：159-163.
[25] DENG Y H， ZENG X， FENG Y， et al. Pharmacokinetics and tolerance of single dose intravenous drip of ginsenoside-Rd injection in Chinese healthy volunteers [J]. Chin J Clin Pharmacol (中国临床药理学杂志)， 2009， 25(2)：116-120.
[26] PENG Y， WANG S J， PAN W S， et al. Pharmacokinetics of ginsenoside Re in rat [J]. J Shenyang Pharm Univ (沈阳药科大学学报)， 2006， 23(4)：197-200.
[27] REN H C， SUN J G， WANG G J， et al. Sensitive determination of 20(S)-protopanaxadiol in rat plasma using HPLC-APCI-MS：Application of pharmacokinetic study in rats [J]. J Pharm Biomed， 2008， 48(5)：1476-1480.
[28] ZHOU W， SHI R B， SUN J N， et al. Pharmacokinetics of effective fractions of Qingnaoxuanqiao Formula in different rat models [J]. J Beijing Unit Tradit Chin Med (北京中医药大学学报)， 2008， 31(4)：265-268.
[29] LI X Y， HAO H P， WANG G J， et al. Integrated pharmacokinetic study of multiple effective components contained in total panax notoginsenosides[J]. Chin J Nat Med (中国天然药物)， 2008， 6(5)：377-381.
[30] SONG M， ZHANG S， XU X， et al. Simultaneous determination of three Panax notoginseng saponins at sub-nanograms by LC-MS/MS in dog plasma for pharmacokinetics of compound Danshen tablets [J]. J Chromatography B， 2010，878(32)：3331-3337.
[31] WANG Z， MA X， CHEN X， et al. Current methods and advances in microbial metabolom ics [J]. Prog Chen (化学进展)， 2010， 22(1)：163-172.
